Arch Therapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Arch Therapeutics Inc announces $2.85 mln private placement
Arch Therapeutics Inc:Says its private placement to institutional and high net worth investors of an aggregate of 11,400,000 shares of common stock at $0.25 per share pursuant to the terms of a securities purchase agreement dated Jan. 30, 2014.Says the private placement is expected to close on or about Feb. 4.Says the gross proceeds of the offering are expected to be about $2.85 mln.Says the net proceeds, after deducting estimated offering expenses payable by Arch, are expected to be about $2.77 mln.Says it not engage a placement agent in connection with the private placement.Says it intends to use the offering proceeds to advance its hemostasis development program, predominantly focusing on AC5 Surgical Hemostatic Device, and for general corporate purposes.
Latest Developments for Arch Therapeutics Inc
- Arch Therapeutics obtains additional positive results for AC5 Surgical Hemostatic Device in Preclinical Safety Study
- Arch Therapeutics Inc announces positive results for AC5 Surgical Hemostatic Device in biochemical and cell function safety studies
- Arch Therapeutics reports positive preclinical data from study of AC5 Surgical Hemostatic Device in animals treated with Brilinta
- Arch Therapeutics Inc reports positive preclinical data from study of AC5 Surgical Hemostatic Device
- Share this
- Digg this